(NAMS) NewAmsterdam Pharma Company N.V. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NAMS) NewAmsterdam Pharma Company N.V. Complete Analysis Pack
Download Your Competitive Advantage
This NewAmsterdam Pharma Company N.V. BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and investment decisions. What you see here is a real preview of the actual report content, not just a placeholder. Buy the full version to get the complete ready-to-use analysis.
Stars
0 marketed drugs
As of end-2025, NewAmsterdam Pharma Company N.V. had no approved commercial product, so it had no market share and no product sales. The company was still in clinical development, led by obicetrapib, and its 2025 revenue was still 0 from marketed drugs.
0 commercial share
NewAmsterdam Pharma Company N.V. still had 0% commercial share because no branded therapy had launched in 2025. The pipeline had not yet turned into product sales, so revenue from commercial operations was still absent. That keeps NewAmsterdam Pharma Company N.V. outside the classic Star box for now.
Clinical-stage only
NewAmsterdam Pharma Company N.V. stayed clinical-stage in 2025, with no product revenue and no commercial sales force.
Value was driven by late-stage obicetrapib trials, including Phase 3 work, not by market launch.
Spending still went mainly to R&D, while promotion stayed minimal because the business was still building data, not selling products.
Single lead asset
NewAmsterdam Pharma Company N.V. is still concentrated on obicetrapib, its only lead asset in Phase 3. In BROADWAY, it lowered LDL-C by 36.3% at week 84, so a successful launch could turn this into a Star.
- One asset drives near-term value
- Phase 3 data support upside
- Single-asset risk stays high
No mature franchise
NewAmsterdam Pharma had no mature franchise because it had no approved, durable product platform, so there was no Star-level cash generation in 2025. Revenue was still pre-commercial, and the value case depended on regulatory approval, launch scale, and payer uptake rather than an established base. That made future Star status possible, but not yet proven.
- No approved franchise in 2025.
- No durable cash flow yet.
- Star status depended on approval and uptake.
NewAmsterdam Pharma: No 2025 Sales, But Obicetrapib Shows Star Potential
NewAmsterdam Pharma Company N.V. was not a Star in 2025: it had 0 product revenue, 0% commercial share, and no approved marketed therapy. The closest Star-like driver was obicetrapib, with Phase 3 BROADWAY showing 36.3% LDL-C reduction at week 84, so Star status still depended on approval and launch.
| Metric | 2025 |
|---|---|
| Product revenue | 0 |
| Commercial share | 0% |
| Lead asset | Obicetrapib |
| BROADWAY LDL-C cut | 36.3% |
What is included in the product
Detailed Word Document
BCG Matrix of NewAmsterdam Pharma: pinpoints pipeline stars, cash needs, and divestment risks across its portfolio.
Editable Excel File
One-page BCG Matrix for NewAmsterdam Pharma Company N.V. to quickly spot growth, cash, and risk areas.
Reference Sources
Lists the key sources behind NewAmsterdam Pharma Company N.V. claims, helping decision-makers verify assumptions quickly and trust the analysis.
Cash Cows
0 approved products
NewAmsterdam Pharma Company N.V. had 0 approved products at end-2025, so it had no mature, low-growth cash engine. Cash cows need an established market leader with steady sales, and NewAmsterdam did not have one. That left the business still dependent on pipeline funding, not product cash flow.
0 product sales
As of FY2025, NewAmsterdam Pharma Company N.V. had 0 product sales, so there was no recurring brand cash inflow to fund operations. That means the Cash Cow box does not fit yet; the business still depends on trial progress and external funding. With no sales base, cash burn stays tied to R&D and pipeline milestones, not operating leverage.
0 recurring cash flow
NewAmsterdam Pharma Company N.V. was still pre-cash-cow: it had no recurring product cash flow and was using cash to fund R&D. Cash-cow businesses generate more cash than they consume, but NewAmsterdam had not reached that stage yet. Its latest filings still showed a development-stage profile, with cash burn tied to pipeline work rather than steady operating inflows.
No dividend base
NewAmsterdam Pharma Company N.V. has no dividend base because it has no commercial cash pool from product sales to fund payouts or debt service. Its cash flow has been tied to financing activity, not operating surplus, so any excess cash would come from equity or debt raises, not a cash-cow business unit. That is why this BCG Matrix point fits a pre-commercial biotech profile.
- No operating cash cow
- No dividend-supporting cash pool
- Cash, if any, came from financing
No mature margins
NewAmsterdam Pharma Company N.V. had no mature, high-margin products in 2025, and it still had no product revenue, so there was no cash-cow engine to fund growth. Its economics were still dominated by R&D and clinical trial spend, which is typical for a development-stage biotech and the opposite of a mature-margin profile. That keeps this bucket out of the Cash Cows box in the BCG matrix.
- No product sales, no mature margins.
- R&D and trials drove costs.
- Pre-commercial biotech, not cash cow.
NewAmsterdam Pharma: No Cash Cow, Still Pre-Commercial in FY2025
NewAmsterdam Pharma Company N.V. had no Cash Cow in FY2025: it reported 0 product sales, 0 approved products, and no recurring operating cash inflow. Cash use stayed tied to R&D and clinical work, so the business remained pre-commercial and dependent on financing, not mature product cash flow.
| FY2025 metric | Value |
|---|---|
| Approved products | 0 |
| Product sales | 0 |
| Cash cow status | None |
Preview the Actual Deliverable
NewAmsterdam Pharma Company N.V. Reference Sources
You're previewing the exact NewAmsterdam Pharma Company N.V. BCG Matrix file you'll receive after purchase. The full document is the same professionally formatted version, with no demo content or watermarks. Once purchased, it’s ready for immediate download, editing, or presentation. What you see here is precisely what you’ll get.
Dogs
0 legacy brands
NewAmsterdam Pharma Company N.V. had 0 legacy brands, so there was no Dogs segment to manage down. The company was still a development-stage biotech, with no approved commercial products in fiscal 2025 and no mature, low-growth brands to harvest or exit.
That fits the BCG rule: Dogs usually are weak, late-stage products with low growth and low share, but NewAmsterdam Pharma Company N.V. had not reached that stage. Its 2025 spending stayed focused on R&D, not on defending old brands.
0 obsolete products
NewAmsterdam Pharma Company N.V. disclosed 0 commercial products in its portfolio, so there was no obsolete asset to classify as a low-growth, low-share drag. The company’s base was still developmental, led by late-stage pipeline work rather than marketed revenue streams. In FY2025/FY2026 terms, the BCG "Dogs" bucket stayed empty.
0 low-share mature units
NewAmsterdam Pharma Company N.V. had no marketed product in 2025/2026, so it had no mature, low-share business unit to place in the Dogs quadrant. With zero commercial sales and no established market position, the classic Dog profile of a mature market plus weak share does not apply. In BCG terms, this quadrant is effectively empty.
0 divestiture assets
Dogs are 0 divestiture assets for NewAmsterdam Pharma Company N.V. in 2025, because there was no non-core commercial unit to sell or shut down. The pipeline was still being advanced, led by obicetrapib, so the company stayed a pure clinical biotech rather than a portfolio with disposal candidates.
That fits the BCG logic: no harvestable legacy asset, no cash from asset sales, and no Dogs bucket to trim. The key value driver remained R&D execution, not divestiture.
- No non-core asset was visible for sale.
- No shutdown candidate was disclosed.
- Pure clinical biotech profile stayed intact.
- Main asset was still in development.
0 turnaround dogs
NewAmsterdam Pharma Company N.V. has 0 turnaround dogs because there was no weak legacy product to fix. This is a development-stage story, so the main risk was trial success, not costly product repair or brand rescue.
- No legacy franchise to turn around
- Risk sat in clinical readouts
- Capital went to R&D, not rescue
NewAmsterdam Pharma: No Dogs, All R&D
NewAmsterdam Pharma Company N.V. had no Dogs in FY2025/FY2026 because it had 0 commercial products, 0 legacy brands, and no divestiture assets. Its capital still went to R&D, with obicetrapib as the core development program. In BCG terms, the Dogs bucket stayed empty.
| Metric | FY2025/FY2026 |
|---|---|
| Commercial products | 0 |
| Legacy brands | 0 |
| Dogs | 0 |
Question Marks
Obicetrapib
Obicetrapib is NewAmsterdam Pharma Company N.V.’s lead CETP inhibitor and main value driver, built to lower LDL-C and raise HDL-C. By end-2025, it was still a high-upside but unproven commercial bet, with Phase 3 results shaping its market case. In BCG terms, it fits a Question Mark: big potential, but not yet a proven cash generator.
Obicetrapib plus ezetimibe
Obicetrapib plus ezetimibe is a Question Mark because the combo is built to drive deeper LDL-C lowering than either drug alone, but it still had zero commercial share and no product sales as of 2025.
It targets a huge lipid-lowering market: the American Heart Association says about 94 million U.S. adults have total cholesterol of 200 mg/dL or higher, so demand is real.
Still, its value depends on late-stage data and approvals, so NewAmsterdam Pharma Company N.V. must turn clinical wins into launch sales first.
BROADWAY
BROADWAY is NewAmsterdam Pharma Company N.V.'s late-stage phase 3 obicetrapib program, built on data from 2,530 high-risk patients with ASCVD or HeFH. In the trial, obicetrapib 10 mg cut LDL-C by 29.9% at day 84 versus placebo, showing clear launch potential.
Still, until full regulatory approval is secured, BROADWAY stays a classic Question Mark in the BCG Matrix.
PREVAIL
PREVAIL is NewAmsterdam Pharma Company N.V.'s Phase 3 cardiovascular outcomes trial for obicetrapib, and it is the key Question Mark in the BCG Matrix. If it shows fewer major adverse cardiovascular events, it can strengthen the label and support broad use; if not, the asset's long-term value drops fast.
The upside is large, but the risk is binary and clinical, not just commercial. Until outcomes data read out, PREVAIL stays a high-potential, high-uncertainty program that can swing NewAmsterdam Pharma Company N.V.'s valuation and adoption path sharply either way.
- Phase 3 outcomes trial
- Label strength depends on data
- Binary readout risk remains
- Big upside, but still uncertain
TANDEM
TANDEM sits in NewAmsterdam Pharma Company N.V.’s LDL-C push and adds evidence for obicetrapib-based therapy. It was still pre-commercial at end-2025, so its value in the BCG Matrix is closer to a Question Mark than a cash generator. The program matters because it can widen the clinical case for the company’s lead CETP inhibitor across the 2025 pipeline.
- LDL-C strategy support
- Builds obicetrapib evidence
- Pre-commercial at end-2025
NewAmsterdam’s Pre-Commercial Pipeline Hinges on Phase 3 Readouts
Question Marks in NewAmsterdam Pharma Company N.V. are still pre-commercial bets. Obicetrapib, BROADWAY, PREVAIL, and TANDEM had pipeline upside in 2025, but no product sales yet, so value depended on Phase 3 data and approvals.
| Item | 2025 status |
|---|---|
| Obicetrapib | Lead Question Mark |
| BROADWAY | 2,530 pts |
| PREVAIL | Outcomes readout pending |
| TANDEM | Pre-commercial |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.